


Case/UH AIDS Clinical Trials Unit			December 2016	For more information on Case/UH clinical trials please contact Jane Baum, RN at (216)844-2546 or baum.jane@clevelandactu.org
What It Does		How It Does It		Who Can Participate
Inflammation				
A5332 REPRIEVE	72-month, placebo-controlled phase 4 study to determine effect of pitavastatin as primary preventive therapy on CVD events. Enrolling people on ART not meeting 2013 ACC/AHA guidelines for statin recommendation. Compensation and mileage reimbursement provided.	Two arm trial. 1:1 randomization. Arm A: pitavastatin 4 mg daily Arm B: Placebo daily. Women of reproductive capacity must agree to use approved forms of contraception.		HIV+people, ages 40 ≥ and ≤ 75. On ART ≥ 6 mos. CD4+ >100. No clinical ASCVD, as defined by 2013 ACC/AHA guidelines, including a previous diagnosis of any of the following: AMI; Acute coronary syndromes; Stable or unstable angina; Coronary or other arterial revascularization; Stroke; TIA; Peripheral arterial disease presumed to be of atherosclerotic origin. Cancer free > 3 years. No known cirrhosis. No untreated symptomatic thyroid disease.
5336	12 week, randomized, open-label trial of ruxolitinib to determine safety/tolerability and changes in systemic immune activation and inflammation. Compensation provided.	Participants take study drug for 5 weeks. 2:1 randomization to Arm A: Ruxolitinib 10 mg orally BID + participant’s ART regimen Arm B: ART regimen (no study drug). ART regimen not provided by study.		HIV+ adults 18 to 75 years old; CD4>350. On continuous ART >2 yrs with documented viral suppression >2 yrs. (One blip ≤ 500 allowed in 2 nd yr before entry). No changes in ART<12 wks prior to entry. ART must contain TDF/FTC, TAF/FTC,TDF+3TC, or ABC/3TC plus NNRTI or INSTI, not containing cobicistat (no Stribild). No history of PML.
Neurocognition				
5324 HAND	OPEN 96 week, placebo-controlled clinical trial to determine if adding maraviroc and/or dolutegravir reduces HIV-associated neurocognitive disorder. Compensation provided.	Participants will be randomized to one of three arms Arm A: placebo for maraviroc and placebo for dolutegravir Arm B: dolutegravir and placebo for maraviroc Arm C: maraviroc and dolutegravir		HIV+ adults ≥ 18 years. On current ART ≥ 12 months. HIV VL <50. No more than one viral load 50 to 200 within the last 6 months. At least mild HAND based on testing done at screening. No medical condition not related to HIV which may cause cognitive impairment. No current hepatitis C. No prior/current use of integrase inhibitor or maraviroc.
Hepatitis C Co-infection				
5329	Non-randomized, open label, Phase II study of IFN-free hep C therapy for either 24 or 12 weeks in co-infected people. Prelim data from Phase III in mono-infected hep C of same study drugs yielded SVR rates of ≥ 92%. Study drugs: HCV DAA of ABT-450/ABT-267 plus ABT-333 and RBV.	ABT-450/r/ABT-267 (150/100/2f mg) by mouth once a day plus ABT-333 (250 mg) by mouth twice a day plus Ribavirin 1000-1200 mg (based on wt) divided into 2 doses (twice a day). Subjects will be treated for either 12 or 24 wks, but neither subject nor provider will be able to choose duration of treatment. All subjects followed for 48 weeks on study.		HIV+ adults 18-70 yrs; HIV VL <50; no history of HIV virologic failure; no HIV genotypic resistance to any ARV. CD4 ≥ 200; CD4 cell % ≥14%. BMI: ≥18 to ≤38 kg/m2. Must be on specific ARVs ≥ 8 wks: a. Tenofovir plus emtricitabine qd(or fixed-dose Truvada) or tenofovir plus lamivudine qd (or fixed dose TDF/3TC), <u>plus</u> b. raltegravir 400 mg bid or darunavir 800 mg qdwith ritonavir 100 mg qd. HCV VL >10,000, HCV genotype 1. HCV treatment naïve (few exceptions). No history of decompensated liver disease; no active depression/uncontrolled mental health disorders. Not pregnant/breastfeeding or have partner who is pregnant.

What It Does		How It Does It	Who Can Participate
Trials for HIV-Negative People			
HVTN 704 AMP Study	Randomized, placebo-controlled phase IIb trial evaluating safety and efficacy of a broadly neutralizing monoclonal antibody (VRC01) in reducing acquisition of HIV-1 infection. Compensation provided.	Each participant will be in the trial for 21 months; clinic visits approximately monthly. At 10 visits (every other month), participants will receive VRC01/placebo through infusion. Ongoing HIV risk reduction counseling provided. Participants have option to obtain PrEP drugs through trial at no cost.	HIV-negative MSM (transgender men inclusive) and transgender women who have sex with men, ages 18-50. Good general health. Body mass index < 40. No asthma, other than mild, well-controlled asthma. Sexual history taken at screening visit.
HVTN116	OPENING SOON. Randomized, open-label, Phase I trial to evaluate safety, pharmacokinetics and anti-viral activity of VRC01 and VRC01LS, in the serum and mucosa of HIV-negative adults. VRC01LS is variant of VRC01, altered for longer half-life.	Two arm trial: Arm 4: Receipt of one VRC01 infusion, with 6 mos f/u Arm 5: Receipt of one VRC01LS infusion, with 12 mos f/u. During f/u periods, multiple serum and genital/rectal secretions samples, genital/rectal biopsies taken.	HIV-negative healthy adults, ages 18-50. Weight ≤ 115 kg. Assessed by clinical staff as ‘low risk for HIV infection’. No asthma other than mild, well-controlled asthma.
Our physicians welcome calls/emails from other HIV-treating physicians who would like to discuss a clinical issue with them Barbara Gripshover, MD: antiretroviral medications; resistance; co-infections. 216.844.5876 gripshover.barb@clevelandactu.org Michael Lederman, MD: immunopathogenesis; immune-based therapies; clinical management. 216.844.8786 MXL6@case.edu Michelle Lisgaris, MD: women’s health; gender differences. 216.844.6289 MVL@case.edu Grace McComsey, MD: metabolic and cardiovascular complications; pediatric HIV. 216.844.3645 cactumg@clevelandactu.org Benigno Rodriguez, MD: immunopathogenesis; coinfections; clinical outcomes. 216.844.2057 rodriguez.benigno@clevelandactu.org Robert Salata, MD: international HIV; clinical management, trials, and outcomes; women’s health; resistance. 216.844.3287 ras7@case.edu			